Results

1–8 of 8 results for cell therapy

Phase 3 Randomized Studies of Efficacy and Safety of Revakinagene Taroretcel Producing Ciliary Neurotrophic Factor (CNTF) in Macular Telangiectasia Type 2
Emily Y. Chew, MD
Annual Meeting Talks
2023
Stem Cell Therapy for Retinal Disease: Where Are We Now?
Susanna S. Park, MD, PhD
Updates from the Field
2022
Intravitreal Injection of Allogeneic Human Retinal Progenitor Cells for Treatment of Retinitis Pigmentosa: Results from the Phase 2b Trial
Anthony Joseph, MD
Annual Meeting Talks
2020
Rho Kinase Inhibition Reduces Photoreceptor Damage After Retinal Detachment: Possible Implications for Gene and Cell Therapy
Marco A. Zarbin, MD, PhD
Updates from the Field
2021
Cell Therapies for Atrophic AMD
Allen C Ho, MD FASRS
Updates from the Field
2020
Interim Results and Key Learnings from an Ongoing Phase 2 Study of Encapsulated Cell Therapy Compared to Aflibercept in Patients With Wet AMD
Szilárd Kiss, MD
Annual Meeting Talks
2016
Direct-to-Consumer Marketing by U.S. Cell Therapy Clinics for Retinal Conditions
Ajay E Kuriyan, MD, MS
Annual Meeting Talks
2018
Stem Cell Therapy
Mark S. Humayun, MD, PhD
Updates from the Field
2017